


ABSTRACT

This invention relates a to a series of heterocyclic substituted piperazines of Formula I



I

pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the  $\alpha$ -1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.